Call 2014: Mouse models and rare diseases

Similar documents
Call 2013: Mouse models and rare diseases

Call 2014: Small animal models and rare diseases

Use of Gene Editing Technologies in Rodents. Carlisle P. Landel, Ph.D.

The International Mouse Phenotyping Consortium (IMPC)

The INFRAFRONTIER Research Infrastructure Michael Hagn Helmholtz Zentrum München

Bart Williams, PhD Van Andel Research Center

CRISPR/Cas9 Mouse Production

Transgenesis. Stable integration of foreign DNA into host genome Foreign DNA is passed to progeny germline transmission

Theoretical cloning project

Mouse Engineering Technology. Musculoskeletal Research Center 2016 Summer Educational Series David M. Ornitz Department of Developmental Biology

Human Molecular Genetics Assignment 3 (Week 3)

Embryonic development, epigenics and somatic cell nuclear transfer - The science and its social implications -

Mouse Genetics 3/8/17. Outline. History of Mouse Genetics. History of the laboratory mouse. Mouse strains. Gene8c mapping How do we find genes?

TRANSGENIC ANIMALS. transient. stable. - Two methods to produce transgenic animals:

Chapter 5 Genetic Analysis in Cell Biology. (textbook: Molecular Cell Biology 6 ed, Lodish section: )

Genomic Medicine in France

The Use of Genetically-Modified Mouse Models to Study the Actin Cytoskeleton

EMMA - European Mouse Mutant Archive Michael Hagn

Genetically Modified Animals. Code: ECTS Credits: 6. Degree Type Year Semester Biomedical Sciences OT 4 0

CRISPR Applications: Mouse

7.03, 2005, Lecture 25 Transgenes and Gene Targeting in Mice II

Lecture 8: Transgenic Model Systems and RNAi

Incorporating SeqStudio Genetic Analyzer and Sanger sequencing into genome editing workflows

Course Agenda. Day One

Experimental genetics - 2 Partha Roy

ICH Considerations. Oncolytic Viruses September 17, 2009

TRANSGENIC TECHNOLOGIES: Gene-targeting

Germline Gene Therapy

LS4 final exam. Problem based, similar in style and length to the midterm. Articles: just the information covered in class

Lectures 28 and 29 applications of recombinant technology I. Manipulate gene of interest

Easi CRISPR for conditional and insertional alleles

What goes into my Biological Inventory?

Human Genome Editing: Science, Ethics, and Governance Highlights for Industry Stakeholders

KOMP2 EVOLUTION OF THE VISION. Athens, Infra frontier, IPAD MD, IMPC

Regulatory Pathways for Rare Diseases

species- Mus musculus Engineering the mouse genome David Ornitz

CRISPR-Cas9 Genome Editing. New Era of Agricultural Biotechnology

(i) A trp1 mutant cell took up a plasmid containing the wild type TRP1 gene, which allowed that cell to multiply and form a colony

Zebrafishing in Lisbon

Generating genetically modified model marmoset. Erika Sasaki Central Institute for Experimental Animals CIEA SINCE 1952

Generation and Application of Genetically Modified Mouse Models of Human Disease.

University of Delaware Department of Environmental Health & Safety Recombinant DNA Registration

Analysis of gene function

Yale University Biological Safety Committee

Technical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products

Chapter 15 The Human Genome Project and Genomics. Chapter 15 Human Heredity by Michael Cummings 2006 Brooks/Cole-Thomson Learning

TRANSGENIC ANIMALS. -transient transfection of cells -stable transfection of cells. - Two methods to produce transgenic animals:

SDR and SRG SCID Rats

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform

Name Class Date. a. identify similarities and

11:20-11:50 Genome Editing in Argentina: Initiatives and Prospective

The Use of Genetically-Modified Mouse Models to Study the Cytoskeleton

Thoughts on Gene Editing Francis Collins, M.D. U.S. National Academies Human Gene Editing Committee July 12, 2016

ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008

Student Learning Outcomes (SLOS) - Advanced Cell Biology

Hemophilia and Gene Therapy

TRIANNI Media Kit MEDIA CONTACT CORPORATE HEADQUARTERS. Trianni, Inc. San Francisco, CA

Assessing welfare and severity of GA mice under Directive 2010/63/EU. James Bussell Wellcome Trust Sanger Institute

Introducing new DNA into the genome requires cloning the donor sequence, delivery of the cloned DNA into the cell, and integration into the genome.

GENOME 371, Problem Set 6

Genetics - Problem Drill 19: Dissection of Gene Function: Mutational Analysis of Model Organisms

The Use of Genetically-Modified Mouse Models to Study the Cytoskeleton

B6 Albino A ++ Mutant Mice as Embryo Donors for Efficient Germline Transmission of B6 ES Cells. Taconic Webinar Prof. Dr.

4th Annual. 7th & 8th February 2019 San Diego-CA

Food regulatory perspective on gene editing

John Gurdon was testing the hypothesis of genomic equivalence or that when cells divide they retain a full genomic compliment.

NPBT in the European Union: Experience, regulation and existing guidance

Personalized Human Genome Sequencing

Q Earnings and Corporate Developments. October 31, 2018

Adding CRISPR to Your Bio-ARROW Protocol

The NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines)

The Swedish Foundation for Strategic Research (SSF) announces a. call for proposals in the areas of

Stem Cel s Key Words:

Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy

ICH CONSIDERATIONS Oncolytic Viruses

SUPPLEMENTARY INFORMATION

Introduction to CRISPR/Cas9 Background DNA Cleavage and Repair (NHEJ and HDR) Alternative Cas9 Variants Delivery of Cas9 and sgrna Library Products

Recent Initiatives in Precision Medicine PMC Policy Committee Meeting February 20, Laura Koontz, Ph.D. Personalized Medicine Staff CDRH/OIR

7.03 Final Exam Review 12/19/2006

Transgenic Mice. Introduction. Generation of Transgenic Mice. Transgenic Mice: A Unique Tool for the Study of Mammalian Biology.

Personalised Medicine Regulatory Issues

CRISPR ways to understand gene-environment interactions

TRANSLATIONAL RESEARCH IN RARE AND NEUROMUSCULAR DISEASES - WHY DATA SHARING MATTERS. H a n n s Lochmüller, Newcastle University

The International Mouse Phenotyping Consortium (IMPC)

Genetics and Genomics in Medicine Chapter 9 Questions

[Presented by: Andrew Howlett, Cruise Slater, Mahmud Hasan, Greg Dale]

7.03 Exam 3 Review GENE REGULATION

IBC protocol Risk Assessment and Determination of NIH Guidelines

Efficient generation of conditional knockout mice by CLICK

CRISPR Genome Editing Embryo Microinjection Service Catalog

Our website:

Improving diagnostics and therapeutics for Mendelian diseases using precision mouse models

Application for Research Involving Biological Materials and Recombinant DNA

Biomarker Regulation. Regulator s perspective. Jan Müller-Berghaus

Frequently Asked Questions (FAQs) of Interest to IBCs

B6 Albino Mouse Models

Charles Shuler, Ph.D. University of Southern California Los Angeles, California Approved for Public Release; Distribution Unlimited

GVSU BIOSAFETY APPLICATION

TITLE: Mammary Specific Expression of Cre Recombinase Under the Control of an Endogenous MMTV LTR: A Conditional Knock-out System

Using CRISPR for genetic alteration

Transcription:

Call 2014: Mouse models and rare diseases The French Foundation for rare diseases (Fondation maladies rares) and the French National Infrastructure PHENOMIN, which includes the Institut Clinique de la Souris (ICS, Illkirch), the Centre for Immunophenomics (CIPHE, Marseille) and the Transgenesis and Archiving of Animal Models (TAAM, Orléans, Villejuif) are pleased to launch their 2 nd joint call for the creation and exploration of mouse models for rare diseases. Submission deadline for proposals: January 13, 2015, 5:00 pm A Context and aims of the call The call for projects 'Mouse models and rare diseases' aims to give a significant boost to the development of mouse models, in order to: gain a better understanding of the pathophysiological mechanisms involved in rare diseases whose defective genes have been identified; test and validate therapeutic proofs of concept, at the pre- clinical in vivo level. Indeed, producing these models meets a key objective in the development of a therapeutic strategy. After their initial in vitro testing, therapeutic proofs of concept must be tested in a living model that recapitulates as closely as possible both the phenotype and biological defects associated to the human disease. Such a model should provide appropriate data regarding the safety and the efficiency of the drug, thus evaluating its benefit/risk ratio, prior to conducting early phases of a therapeutic trial. PHENOMIN and the French Foundation for rare diseases combine their efforts in order to achieve these objectives through the joint call for proposals for the generation and characterization of mouse models, dedicated to rare diseases. This action is part of the objectives of PHENOMIN to develop mouse model resources that will be made available to the scientific community. B Content of the call for proposals (see the summary diagram in Appendix) This call for proposals is open to research projects covering all rare diseases. For rare cancers, the French National Cancer Institute, INCa, and the French Foundation for rare diseases have defined jointly the following criteria: projects concerning primary malignant tumors should be addressed to INCa, projects concerning benign tumors as well as systemic rare diseases involving tumor development will be evaluated within this call. The principal investigator of the project must belong to a French research team, affiliated to academia (research team working in universities, other higher education institutions or research institutes) and/or to clinical/public health sector (research team working in state or university hospitals/public health organizations). The aim of the call is in compliance with the goals set by the International Rare Diseases Research Consortium (IRDiRC). Call for projects Mouse models and rare diseases - Fondation maladies rares / Phenomin November 2014 page 1

One distinct submission form must be filled per independent mouse model. The call is dedicated to generating mouse models and standard phenotyping. Any other request (breeding, specific phenotyping, ) is not eligible. 1- Generation of mouse models a. Knock- Out constitutive, conditional mice: Knock- Out models will be generated either: 1) from ES cells derived from the international IMPC resource (www.knockoutmouse.org). Models will be generated on a C57BL/6N genetic background. Knock- Out models with conditional potential (KO- first allele, tm1a) will be first produced; Knock- out by disruption of a critical exon (knock- out tm1b allele) and Conditional Knock- Outs (cko tm1c allele) can then be provided by using Cre/LoxP and Flp/FRT systems. KO- first allele, tm1a is provided, tm1c or tm1b alleles are provided on request: 2) In case of ES clones unavailability from the IMPC resource, constitutive Knock- Out models will be generated by the CRISPR/Cas9 nuclease technology (C57BL/6N genetic background only), conditional Knock- Out models will be generated de novo by ES- based methods (on different genetic backgrounds: C57BL/6N, BALB/cN, 129Sv/Pas). b. Knock- In mice: Knock- In mice [reporter gene, point mutation, humanization, targeted transgenesis (ROSA26), but excluding complex modifications] will be generated de novo by the PHENOMIN infrastructure. Knock- In mice can be generated on different genetic backgrounds: C57BL/6N, BALB/cN, 129Sv/Pas. Call for projects Mouse models and rare diseases - Fondation maladies rares / Phenomin November 2014 page 2

c. Transgenic mice: Transgenic mice (overexpression by pronuclear injection in C57BL/6N fertilized oocytes, but excluding complex constructs) will be generated de novo by the PHENOMIN infrastructure. 2- Expansion and phenotyping All Knock- Out models (with conditional potential) derived from the IMPC resource and KO generated by CRISPR/Cas9 will be phenotyped according to a standard scheme defined by the members of the international consortium IMPC (www.mousephenotype.org). Models generated de novo by the PHENOMIN infrastructure can be phenotyped according to the same scheme, at the request of the principal investigator and after assessment of the application - the added value to achieve a global standard phenotype will be evaluated. IMPReSS standard phenotyping scheme 3- Models generation, phenotyping and data availability to the investigator and to the scientific community Models generated from the IMPC resource will be sent to the principal investigator of the project within 8 to 16 months after obtaining necessary information and materials to start the project. The majority of projects are completed within 12 months following the initiation of the project. More time may be necessary in a few cases, depending on the time needed to obtain the IMPC clones or to achieve the targeting constructs. Call for projects Mouse models and rare diseases - Fondation maladies rares / Phenomin November 2014 page 3

Models generated de novo will be provided to the principal investigator within an average of 18 months (minimum period: 12 months). The progress of each project will be monitored and updated every 6 months by the PHENOMIN project manager and communicated to the principal investigator. Phenotypic data will be available within 16 to 24 months after delivery of the model to the principal investigator. According to the IMPC consortium rules, Knock- Out first models (with conditional potential) generated from this resource and knock- out models generated by CRISPR/Cas9 genome editing technology will be made available to the principal investigator of the project and to any interested group, as soon as germline transmission is confirmed. Similarly, phenotypic data will be made available to the scientific community through a single database accessible on the web. The IMPC program provides a single web- based database referencing all resources. Any model already completed or underway in the world is thus made available to any interested group almost in real time. Models generated de novo by the PHENOMIN infrastructure will be provided first to the principal investigator. Models will be preserved and archived and will then be made available to the whole scientific community within 24 months. The IMPC standard phenotypic data will be made available to the community within 12 months. Diagram of time provision of models and phenotypic data C Technical evaluation Technical feasibility and eligibility of the project must be checked and approved by the platform before submission. The PI must contact PHENOMIN using contact@phenomin.fr for submitting the synopsis of the project (10 lines maximum) with a clear reference to the MGI reference gene and the type of model required, within the subject field Call 2014: Mouse models for rare diseases. A conference call will be scheduled in order to address the feasibility and define the most suited design for the project, with associated quoting elements. This procedure is mandatory and should be planned early in the process in order to ensure timely submission of the project. Call for projects Mouse models and rare diseases - Fondation maladies rares / Phenomin November 2014 page 4

1. Knock- Out constitutive, conditional models: Several cases are possible. Case 1: The model is already available or is developed by another IMPC resource center. In this case, the proposal is not eligible. The principal investigator will be informed of the corresponding center. Case 2: Three ES mutant clones with conditional inactivation of the gene are available. These clones are referred to as "clones with conditional potential" on the IMPC website (www.knockoutmouse.org). In this case, only the recombinant ES clones generated by the consortium IMPC will be used for successful applications. Case 3: For projects that do not match any of the two afore mentioned cases. The de novo creation of the Knock- Out [constitutive, conditional] model (based on information available) will be evaluated specifically. 2. Knock- In models: For targeted mutations, projects will only be initiated if corresponding to a point mutation or several mutations in the same region. For humanization or reporter models, complex designs are not supported. Only C57BL/6N, BALB/cN and 129Sv/Pas genetic backgrounds are available. 3. Transgenic models: Only injections of a single transgene will be made. Complex constructs cannot be processed. Generation of more than two lines and overexpression of the transgene cannot be guaranteed. Only C57BL/6N genetic background. D Scientific evaluation Submitted projects will be evaluated by two external referees and then selected by a scientific ad hoc committee, composed of members of PHENOMIN and members of the Scientific Advisory Board of the French Foundation for rare diseases. Evaluation criteria: The following elements will be particularly considered in the evaluation of the project: Relevance and originality of the project; Relevance and quality of scientifically validated preliminary data; Relevance of the animal model for human disease; Integration of the project in the research program of the applicant; Positioning of the project in the national and international context; Clarity of objectives and outcomes of the project; Team experience in mouse model exploration and animal room facilities; Respect of animal ethical rules; Prospects in terms of future development and capitalization of emerging data. Call for projects Mouse models and rare diseases - Fondation maladies rares / Phenomin November 2014 page 5

E Funding Successful applicants will receive financial support for the establishment of the mouse model - Knock- Out [constitutive, conditional], Knock- In and transgenic mice - the expansion of the model (in case of standard phenotyping only) and phenotyping according to the standard scheme defined by the international consortium IMPC. Funding will cover costs of services provided by the platform and is not intended to cover equipment, running costs or personnel costs in the researcher s laboratory. For successful applications, if a conditional Knock- Out model is under development at that time in another center from the IMPC consortium, the latter will not be generated again by PHENOMIN. Financial support will cover the cost of transfer of the model for a maximum amount of 3 000. F Proposal submission and schedule of the call Application forms are available on websites of the French Foundation for rare diseases (www.fondation- maladiesrares.org) and PHENOMIN (www.phenomin.fr) or upon request by using: modeles_murins@fondation- maladiesrares.com. Each submitted form must be related to only one model. Application forms must be sent by email to: modeles_murins@fondation- maladiesrares.com and by post mail (one original signed form) to: Fondation maladies rares, Appel à projets Modèles murins et maladies rares, 96 rue Didot, Plateforme Maladies Rares, 75014 Paris. Schedule of the call for proposals: Submission deadline for proposals: January 13, 2015 (5:00 pm). Evaluation process: - Scientific evaluation by two external referees (January- February 2015) - Selection by a scientific ad hoc committee, composed of members of PHENOMIN and members of the Scientific Advisory Board of the French Foundation for rare diseases (March 2015). The title of the selected projects and name of their principal investigator will be published on both websites of The French Foundation for rare diseases and PHENOMIN by April 2015. Call for projects Mouse models and rare diseases - Fondation maladies rares / Phenomin November 2014 page 6

Appendix: Summary diagram of the call" Call 2014: Mouse models and rare diseases Fonda7on maladies rares & Phenomin Submission of the project: modeles_murins@fonda0on- maladiesrares.com Selec7on through scien7fic and technical evalua7on Models available or under development in another IMPC center www.knockoutmouse.org Connexion with the corresponding IMPC center Repatria7on of the model to the laboratory Targeted mutagenesis Models generated star7ng from ES cells with condi7onal gene inac7va7on available (IMPC resource) www.knockoutmouse.org Knock- Out with condi0onal poten0al KO first - tm1a allele KO tm1b allele Condi0onal KO (cko) tm1c allele Ordering ES clones Implementa7on of the model CRISPR/Cas9 Models generated de novo Cons0tu0ve Knock- Out Genera7on of the model from A to Z Random transgenesis Pronuclear injec0on BAC injec0on Plasmid injec0on ES cells Cons0tu0ve Knock- Out (KO) Condi0onal Knock- Out (cko) Knock- In (KI) Point Muta0on (PM) Humaniza0on Reporter gene Targeted transgenesis (ROSA26) Standard Phenotyping (IMPC) of KO first model Included Standard phenotyping (IMPC) Upon request